A new strategy in the treatment of chemoresistant lung adenocarcinoma via specific siRNA transfection of SRF, E2F1, Survivin, HIF and STAT3

European Journal of Cardio-thoracic Surgery

Volumn 46, Issue 5, 2014, Pages 877-886

  Stoleriu, Mircea Gabriel ^a   Steger, Volker ^a   Mustafi, Migdat ^a   Michaelis, Martin ^b   Cinatl, Jindrich ^c   Schneider, Wilke ^a   Nolte, Andrea ^a   Kurz, Julia ^a   PeterWendel, Hans ^a   Schlensak, Christian ^a   Walker, Tobias ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF KENT   (United Kingdom)

^c Department of Pediatric Cancer and Virus Research ^*  (Germany)

Author keywords

Chemoresistance; Multimodality concept; NSCLC; siRNA; Target molecules

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1; METHOTREXATE; NAVELBINE; SERUM RESPONSE FACTOR; SMALL INTERFERING RNA; STAT3 PROTEIN; SURVIVIN; TRANSCRIPTION FACTOR E2F1; VINFLUNINE; ANTINEOPLASTIC AGENT; BASIC HELIX LOOP HELIX TRANSCRIPTION FACTOR; BIRC5 PROTEIN, HUMAN; E2F1 PROTEIN, HUMAN; ENDOTHELIAL PAS DOMAIN-CONTAINING PROTEIN 1; INHIBITOR OF APOPTOSIS PROTEIN; SRF PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; VINBLASTINE;

A549 CELL LINE; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RESISTANCE; CASY CELL COUNTER; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; LUNG ADENOCARCINOMA; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TRANSIENT TRANSFECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADENOCARCINOMA; ANALOGS AND DERIVATIVES; DRUG RESISTANCE; GENE THERAPY; GENETIC TRANSFECTION; GENETICS; LUNG NEOPLASMS; PROCEDURES; RNA INTERFERENCE; TUMOR CELL LINE;

ADENOCARCINOMA; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; E2F1 TRANSCRIPTION FACTOR; GENETIC THERAPY; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; INHIBITOR OF APOPTOSIS PROTEINS; LUNG NEOPLASMS; METHOTREXATE; RNA INTERFERENCE; RNA, SMALL INTERFERING; SERUM RESPONSE FACTOR; STAT3 TRANSCRIPTION FACTOR; TRANSFECTION; VINBLASTINE;

EID: 84933497700     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/ejcts/ezu087     Document Type: Article

References (21)

1. Alberg AJ, Ford JG, Samet JM. Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007;132 (3 Suppl):29S-55S.
2. Chang A. Chemotherapy, chemoresistance and the changing treatment landscape for NSCLC. Lung Cancer 2011;71:3-10.
3. Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997;111:1710-7.
4. D'Amato TA, Landreneau RJ, McKenna RJ, Santos RS, Parker RJ. Prevalence of in vitro extreme chemotherapy resistance in resected nonsmall-cell lung cancer. Ann Thorac Surg 2006;81:440-6.
5. Hildebrandt MA, Gu J, Wu X. Pharmacogenomics of platinum-based chemotherapy in NSCLC. Expert Opin Drug Metab Toxicol 2009;5:745-55.
6. Leonard JN, Schaffer DV. Antiviral RNAi therapy: emerging approaches for hitting a moving target. Gene Ther 2006;13:532-40.
7. Alla V, Kowtharapu BS, Engelmann D, Emmrich S, Schmitz U, Steder M et al. E2F1 confers anticancer drug resistance by targeting ABC transporter family members and Bcl-2 via the p73/DNp73-miR-205 circuitry. Cell Cycle 2012;11:3067-78.
8. Tamm I, Wang Y, Sausville E, Scudiero DA, Vigna N, Oltersdorf T et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998;58: 5315-20.
9. Jiang R, Jin Z, Liu Z, Sun L, Wang L, Li K. Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. Mol Diagn Ther 2011;15:347-52.
10. Foster KA, Oster CG, Mayer MM, Avery ML, Audus KL. Characterization of the A549 cell line as a type II pulmonary epithelial cell model for drug metabolism. Exp Cell Res 1998;243:359-66.
11. Werth D, Grassi G, Konjer N, Dapas B, Farra R, Giansante C et al. Proliferation of human primary vascular smooth muscle cells depends on serum response factor. Eur J Cell Biol 2010;89:216-24.
12. Xue HY, Wong HL. Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer. Eur J Pharm Biopharm 2012;81:24-32.
13. Nolte A, Raabe C, Walker T, Simon P, Ziemer G, Wendel HP. Optimized basic conditions are essential for successful siRNA transfection into primary endothelial cells. Oligonucleotides 2009;19:141-50.
14. Walker T, Nolte A, Steger V, Makowiecki C, Mustafi M, Friedel G et al. Small interfering RNA-mediated suppression of serum response factor, E2-promotor binding factor and survivin in non-small cell lung cancer cell lines by non-viral transfection. Eur J Cardiothorac Surg 2013;43:628-33; discussion 633-4.
15. Wang Y, Wen L, Zhao SH, Ai ZH, Guo JZ, Liu WC. FoxM1 expression is significantly associated with cisplatin-based chemotherapy resistance and poor prognosis in advanced non-small cell lung cancer patients. Lung Cancer 2013;79:173-9.
16. Ren SX, Li AW, Zhou SW, Zhang L, Wang YS, Li B et al. Individualized chemotherapy in advanced NSCLC patients based on mRNA levels of BRCA1 and RRM1. Chin J Cancer Res 2012;24:226-31.
17. Gonzalez de Castro D, Clarke PA, Al-Lazikani B, Workman P. Personalized cancer medicine: molecular diagnostics, predictive biomarkers, and drug resistance. Clin Pharmacol Ther 2013;93:252-9.
18. Minakata K, Takahashi F, Nara T, Hashimoto M, Tajima K, Murakami A et al. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors. Cancer Sci 2012;103:1946-54.
19. Tian H, Liu S, Zhang J, Zhang S, Cheng L, Li C et al. Enhancement of cisplatin sensitivity in lung cancer xenografts by liposome-mediated delivery of the plasmid expressing small hairpin RNA targeting Survivin. J Biomed Nanotechnol 2012;8:633-41.
20. Raparia K, Villa C, DeCamp MM, Patel JD, Mehta MP. Molecular profiling in non-small cell lung cancer: a step toward personalized medicine. Arch Pathol Lab Med 2013;137:481-91.
21. Xie M, He CS, Wei SH, Zhang L. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. Eur J Cancer 2013;49: 3559-72.